Suppr超能文献

通过基因组编辑和同胞选择,对源自心房颤动患者的 hiPSCs 中的杂合性 SHOX2 突变进行精确校正。

Precise Correction of Heterozygous SHOX2 Mutations in hiPSCs Derived from Patients with Atrial Fibrillation via Genome Editing and Sib Selection.

机构信息

Department of Human Molecular Genetics, Institute of Human Genetics, University of Heidelberg, 69120 Heidelberg, Baden-Wuerttemberg, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, Germany.

First Department of Medicine, Cardiology, Klinikum Rechts der Isar - Technical University of Munich, 81675 Munich, Bavaria, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Munich, Munich, Germany.

出版信息

Stem Cell Reports. 2020 Oct 13;15(4):999-1013. doi: 10.1016/j.stemcr.2020.08.015. Epub 2020 Sep 24.

Abstract

Patient-specific human induced pluripotent stem cells (hiPSCs) offer unprecedented opportunities for the investigation of multigenic disease, personalized medicine, and stem cell therapy. For heterogeneous diseases such as atrial fibrillation (AF), however, precise correction of the associated mutation is crucial. Here, we generated and corrected hiPSC lines from two AF patients carrying different heterozygous SHOX2 mutations. We developed a strategy for the scarless correction of heterozygous mutations, based on stochastic enrichment by sib selection, followed by allele quantification via digital PCR and next-generation sequencing to detect isogenic subpopulations. This allowed enriching edited cells 8- to 20-fold. The method does not require antibiotic selection or cell sorting and can be easily combined with base-and-prime editing approaches. Our strategy helps to overcome low efficiencies of homology-dependent repair in hiPSCs and facilitates the generation of isogenic control lines that represent the gold standard for modeling complex diseases in vitro.

摘要

患者特异性人诱导多能干细胞 (hiPSC) 为多基因疾病、个性化医疗和干细胞治疗的研究提供了前所未有的机会。然而,对于心房颤动 (AF) 等异质性疾病,精确纠正相关突变至关重要。在这里,我们从携带不同杂合 SHOX2 突变的两名 AF 患者中生成并纠正了 hiPSC 系。我们开发了一种基于 sib 选择的随机富集的无疤痕纠正杂合突变的策略,然后通过数字 PCR 和下一代测序进行等位基因定量,以检测同基因亚群。这使得编辑细胞富集了 8 到 20 倍。该方法不需要抗生素选择或细胞分选,并且可以轻松与碱基和引物编辑方法结合使用。我们的策略有助于克服 hiPSC 中同源依赖性修复效率低的问题,并促进同基因对照系的生成,这代表了体外模拟复杂疾病的金标准。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7f4/7562944/cec5c1b47c83/fx1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验